SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
Drug Development
AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure
The South San Francisco cuts are not surprising, given that in December the company was forced to halt a Phase III study of Rova-T.
March 29, 2019
 · 
2 min read
 · 
Alex Keown
Business
4 Big Real Estate Buys Benefit Bay Area Biotechs
With pharma and biotech companies fighting for elbow room in the Bay Area where space comes at a premium, it should come as no surprise that some companies are spending big bucks on the space they desire in one of the most vibrant pharma hubs in the world.
March 28, 2019
 · 
2 min read
 · 
Alex Keown
Policy
2 Potential Blockbusters: AbbVie’s Pipeline Looks Promising
On March 26, AbbVie announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved its Skyrizi (risankizumab) for plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who haven’t responded to conventional therapies.
March 27, 2019
 · 
4 min read
 · 
Mark Terry
Business
Exclusive: AbbVie Continues Philanthropic Giving With $40 Million to Build a Middle School
AbbVie is providing a promising future to the town of North Chicago. The pharma company has donated $40 million to build a brand new middle school for the community.
March 25, 2019
 · 
3 min read
 · 
Alex Keown
Policy
Grocer’s Union Sues AbbVie Over Humira Patents
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
March 21, 2019
 · 
3 min read
 · 
Mark Terry
Kena Betancur/Getty Images
BioMidwest
7 Drugs Expected to Be Blockbusters by 2023
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.
March 20, 2019
 · 
5 min read
 · 
Mark Terry
Business
FDA Places Partial Clinical Hold on AbbVie’s Venclexta-Based Multiple Myeloma Trial
In a Phase III trial, a higher proportion of deaths was observed in the venetoclax arm compared to the control arm of the trial.
March 19, 2019
 · 
2 min read
 · 
Alex Keown
BioMidwest
AbbVie’s Humira Remains the Top-Selling Prescription for 2018
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene’s Revlimid earned about half-as-much in 2018.
March 13, 2019
 · 
3 min read
 · 
Alex Keown
Drug Development
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
Takeda Pharmaceutical’s Entyvio outperformed AbbVie’s Humira in a head-to-head comparison in treating ulcerative colitis during a late-stage study, the company said.
March 11, 2019
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Drug Development
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
January 5, 2021
 · 
12 min read
Drug Development
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström’s Macroglobulinemia (WM)
December 23, 2020
 · 
14 min read
BioMidwest
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
December 11, 2020
 · 
17 min read
Drug Development
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
December 10, 2020
 · 
15 min read
BioMidwest
AbbVie Announces Partners in $50 Million Program to Promote Health and Education Equity in Underserved Black Communities
December 9, 2020
 · 
7 min read
Drug Development
Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
December 9, 2020
 · 
17 min read
Drug Development
Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients
December 6, 2020
 · 
22 min read
BioMidwest
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
December 5, 2020
 · 
17 min read
BioMidwest
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
December 5, 2020
 · 
22 min read
Business
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
December 2, 2020
 · 
5 min read
Load More